DOB:

Sex: F

DetoxiGenomic[™] Profile

Physician's Copy



63 Zillicoa Street Asheville, NC 28801 © Genova Diagnostics

Patient: JANE **Order Number:**

> DOE Completed: Received:

Collected: MRN:

Security Code:

PHASE I Detoxification: The First Line of Defense

In Phase I detoxification, enzymes, known collectively as the cytochrome P-450 system, use oxygen to modify toxic compounds, drugs, or steroid hormones. Many toxins must undergo Phase Il detoxification after a reactive site has been formed. Because there are many different toxic compounds the body might encounter, there are many variants of Phase I enzymes.

(CYPIAI) detoxilles poly-
cyclic aromatic hydrocar-
ons (PAHs) produced from
the combustion of organic
materials (exhaust fumes,
charbroiled meats, etc.).
(CYP1B1) is involved in the
4-hydroxylation of estrogen.

(CVD1 A 1) deterrifies poly

(CYP2A6) detoxifies nitrosamines and nicotine

(CYP2C9) detoxifies coumadin® and sulfonylureas.

(CYP2C19) detoxifies proton-pump inhibitors (e.g., prilosec®) and many anticonvulsants (e.g., valium®).

(CYP2D6) detoxifies ~20% of all prescription drugs including tricyclics, MAOIs, SSRIs, opiates, anti-arrhythmics, betablockers, Cimetidine, etc.

(CYP3A4) detoxifies over 50% of all prescription medications and most steroid hormones.

Cytochrome P-450					
Result	Gene	internet information			
V	CYP1A1 *	www.genovations.com/gdgen01			
	CYP1B1 *	www.genovations.com/gdgen02			
V	CYP2A6	www.genovations.com/gdgen10			
	CYP2C9 *	www.genovations.com/gdgen05			
V	CYP2C19 *	www.genovations.com/gdgen06			
V	CYP2D6	www.genovations.com/gdgen03			
	CYP3A4 *	www.genovations.com/gdgen07			

Use of H2 blockers (e.g. Cimetidine) should be avoided as these bind to the heme-containing reactive site of all CYPs inhibiting binding to toxins.

Your Results: Polymorphisms (SNPs) in the genes coding for a particular enzyme can increase or, more commonly, decrease the activity of that enzyme. Both increased and decreased activity may be harmful. Increased phase I clearance without increased clearance in Phase II can lead to the formation of toxic intermediates that may be more toxic than the original toxin. Decreased Phase I clearance will cause toxic accumulation in the body. Adverse reactions to drugs are often due to a decreased capacity for clearing them from the system.

General Therapies to Improve Detoxification:

Foods that generally improve Phase I detoxification and as well improve the efficiency of Phase Il conjugation are generally recommended for individuals with CYP SNPs. These include most vegetables and fruits, but especially cruciferous vegetables (broccoli, Brussels sprouts, cauliflower, watercress, and cabbage), garlic, onions, soy, grapes, berries, green and black tea, and many herbs and spices like rosemary, basil, turmeric, cumin, poppy seeds, and black pepper. Indeed, improving Phase I and Phase II detoxification helps explain why vegetables and fruits protect against many cancers.

Key



Optimal genomic potential - no polymorphism detected Polymorphism detected in this enzyme, increasing your susceptibility to toxins, if exposed

Multiple SNP locations were evaluated for these genes

NR See commentary if applicable.





PHASE II Detoxification: Conjugation of Toxins and Elimination

In Phase II detoxification, large water-soluble molecules are added to toxins, usually at the reactive site formed by Phase I reactions. After Phase II modifications, the body is able to eliminate the transformed toxins in the urine or the feces (through the bile).

(COMT SNP) higher risk for depression, bipolar disorder, ADHD and alcoholism.

			Methylation	
		SNP		
Result	Gene	Location	Internet Information	Affects
+-	COMT	V158M	www.genovations.com/gdv158m	Liver/Gut

(NAT SNP) both slow and rapid acetylators are at increased risk for developing lung, colon, bladder, or head & neck cancer.

(GST SNP) The **GST** isoforms (M1, P1, and T1) are more or less prevalent in various tissues; all catalyze the conjugation of electrophilic compounds with glutathione. Defects in GST activity can contribute to fatigue syndromes, and to various cancers throughout the body.

is present in the cytosol; SOD2 is present in the cytosol; SOD2 is present in the mitochondria. Changes in the SOD enzyme are associated with changes in risk for neurodegenerative disorders like

	Acetylation (N-acetyl transferase)					
SL	OW ME	TABOLIZ	ZER POLY	<u>/MORPHISM</u>		
			SNP			
	Result	Gene	Location	Internet Information	Affects	
		NAT1	R64W	www.genovations.com/gdr64w	All Cells	
		NAT1	R187Q	www.genovations.com/gdr187q	Liver/Gut	
	+-	NAT2	I114T	www.genovations.com/gdi114t	Liver/Gut	
	+-	NAT2	R197Q	www.genovations.com/gdr197q	Liver/Gut	
		NAT2	G286E	www.genovations.com/gdg286e	Liver/Gut	
		NAT2	R64Q	www.genovations.com/gdr64q	Liver/Gut	
FA:	FAST METABOLIZER POLYMORPHISM					
	+-	NAT2	K268R	www.genovations.com/gdk268r	Liver/Gut	

Glutathione Conjugation (Glutathione s-transferase)						
Result	Gene	Location	Internet Information	Affects		
ABSENT	GSTM1	1p13.3	www.genovations.com/gdgstm1	Liver/Kidney		
++	GSTP1	I105V	www.genovations.com/gdgstp1	Brain/Skin		
+-	GSTP1	A114V	www.genovations.com/gda114v	Brain/Skin		

Oxidative Protection							
		SNP					
Result	Gene	Location	Internet Information	Affects			
	SOD1	G93A	www.genovations.com/gdg93a	Cytosol			
	SOD1	A4V	www.genovations.com/gda4v	Cytosol			
++	SOD2	A16V	www.genovations.com/gda16v	Mitochondria			

Your Results: Catechol-O-methyl transferase is the enzyme primarily responsible for breaking down the neurotransmitters dopamine, epinephrine, and norepinephrine.

Your Results: N-acetyl

Transferase detoxifies many environmental toxins, including tobacco smoke and exhaust fumes. Polymorphisms can result in slower than normal or faster than normal addition of an acetyl group to these toxins. Slow acetylators have a build up of toxins in the system and rapid acetylators add acetyl groups so rapidly that they make mistakes in the process. Both slow and rapid acetylators are at increased risk for toxic overload if they are exposed to environmental toxins. If the toxin exposure is reduced, the risk is reduced.

Your Results:

Glutathione-S-transferase detoxifies many water-soluble environmental toxins, including many solvents, herbicides, fungicides, lipid peroxides, and heavy metals (e.g., mercury, cadmium, and lead). The various forms of GST work together to eliminate toxins. Decreased glutathione conjugation capacity may increase toxic burden and increase oxidative stress.

Your Results:

Superoxide Dismutase is an enzyme that protects cells from increased oxidative stress and free radical damage to cell structures like membranes, mitochondria, DNA, and proteins.

Key

Neither chromosome carries the genetic variation.

One chromosome (of two) carries the genetic variation.

Both chromosomes carry the genetic variation.

(You inherit one chromosome from each parent)

Homozygous negative or wild type Heterozygous positive Homozygous positive This test has been developed and its performance characteristics determined by Genova Diagnostics, Inc. It has not been cleared or approved by the U.S. Food and Drug Administration.

Commentary is provided to the practitioner for educational purposes, and should not be interpreted as diagnostic or treatment recommendations. Diagnosis and treatment decisions are the responsibility of the practitioner.

The accuracy of genetic testing is not 100%. Results of genetic tests should be taken in the context of clinical representation and familial risk. The prevalence and significance of some allelic variations may be population specific.

Any positive findings in your patient's test indicate genetic predisposition that could affect physiologic function and risk of disease. We do not measure every possible genetic variation. Your patient may have additional risk that is not measured by this test. Negative findings do not imply that your patient is risk-free.

DNA sequencing is used to detect polymorphisms in the patient's DNA sample. The sensitivity and specificity of this assay is <100%.

Phase I Detoxification (Commentary for polymorphisms may not appear in this section unless the polymorphism has been indicated to have impaired activity.)

Note: In the following charts, substrates, inhibitors, and inducers are listed for each cytochrome P450 enzyme (Phase I) included in the DetoxiGenomic Profile.

Substrates are compounds that are metabolized by that enzyme. The metabolism of some of these compounds is shared by other P450 enzymes (refer to chart).

Inhibitors may or may not be substrates of that enzyme, but will reliably reduce that enzyme's activity if present. **Inducers** also may or may not be substrates, but will tend to increase the enzyme's activity.

Drug Interaction Resources

http://medicine.iupui.edu/flockhart/table.htm

Patient: JANE DOE ID: Page 5

Physician's Copy

CYP1B1

www.genovations.com\gdgen02

There are 2 SNPs measured for this gene that predict risk. In this patient, the specific variants are L432V +/- and N453S negative. The commentary below reflects these results.

Health Implications: Cytochrome P450 1B1 is responsible for the 4-hydroxylation of estrogen as well as the activation of common environmental toxins such as polycyclic aromatic hydrocarbons (e.g., products from cigarette smoke, car exhaust, and charbroiled foods), polychlorinated biphenyls (e.g., PCBs), and aflatoxin B1. Polymorphisms convey a higher capacity for induction with toxin exposure, thus greater activation and potential toxicity of these compounds and greater production of 4-hydroxyestrogens.

Hyperinduction can generate oxidative stress and the 4-hydroxyestrogens may convert to quinone compounds that can cause DNA damage in breast tissue. Polymorphisms have been associated with lower $2:16\alpha$ -hydroxyestrone ratios and increased risk of breast cancer, especially if xenobiotic exposure, high body mass index, long-term HRT, or concomitant CYP1A1 polymorphism. Risk is also increased for cancers of the ovary, prostate, lung and head & neck, especially in smokers.

Minimizing Risk: Do not smoke. Minimize exposure to xenobiotics (e.g., polycyclic aromatic hydrocarbons), also xenoestrogens (e.g., organochlorines), which tend to increase CYP1B1 activity. Eat a diet rich in antioxidants; consider supplementation. Redirect estrogen metabolism away from 4-hydroxylation with cruciferous vegetables and/or agents such as indole 3-carbinol (I3C), diindolylmethane (DIM), fish oils or rosemary.

Use caution with long-term HRT, especially conjugated equine estrogens which are preferentially 4-hydroxylated.

Substrates		Inhibitors	Inducers
Polycyclic aromatic hydrocarbons, (e.g., benzo(a)pyrene) Antidepressants: Amitryiptyline (Elavil) Clomipramine (Anafranil) Imipramine (Tofranil)	Heterocyclic amines Naproxen Propranolol (Inderal) Resveratrol Tacrine (Cognex) Testosterone Theophylline	Cimetidine Ciprofloxacin (Cipro) Erythromycin Fluvoxamine (Luvox) Pyrene Ticlopidine Grapefruit juice (naringenin) Ginseng (possible)	Omeprazole (Prilosec) Phenytoin (Dilantin) Phenobarbital Rifampin Polycyclic Aromatic Hydrocarbons: Cigarette smoke Charbroiled foods
Acetaminophen (NAPQI) Caffeine Clozapine (Clazaril) Coumarin activation Estradiol, Estrone (4-hydroxy	ation)	Officering (possible)	

CYP1B1: Up regulator - is involved in the 4-hydroxylation of estrogen.

CYP2C9

www.genovations.com\gdgen05

Health Implications: Cytochrome P450 2C9 is involved in the metabolism of many drugs including blood thinners like Coumadin ®. Polymorphisms may prevent the normal metabolism of these drugs and side effects are possible. Please refer to the drug pathway chart on the following page.

Minimizing Risks: Your health care provider has a list of drugs cleared through CYP2C9. Consult your physician. You may still need these drugs, but your physician may opt to prescribe a smaller therapeutic dose. Should you need to be placed on a blood thinning agent in the future, make sure your physician knows you have a genetic polymorphism that impairs your ability to break down Coumadin ®. If you are taking aspirin to reduce the risk of colon cancer, switch to a non-aspirin alternative.

Substrates		Inhibitors		Inducers
<u>NSAIDs</u>	<u>Miscellaneous</u>	Anti-	<u>Miscellaneous</u>	Aminoglutethimide
Diclofenac	Continued	<u>depressants</u>	Continued	Aprepitant
Ibuprofen	Febuxostat	Fluvoxamine	Imatinib	Barbiturates
Lomoxicam	Fluoxetine	(Luvox)	Isoniazid	Bosentan
Meloxicam	Flurbiprofen	Paroxetine	Leflunomide	Carbamazepine
S-Naproxen	Fluvastatin	(Paxil)	Lovastatin	Ethanol
Piroxicam	Formoterol	Sertraline	Metronidazole	Griseovulfin
Suprofen	Glyburide	(Zoloft)	(Flagyl)	Phenobarbital
	Hexobarbital	Fluoxetine	Omeprazole	Phenytoin
Oral Hypoglycemic	Hyzaar	(Prozac)	Phenylbutazone	Primidone
<u>Agents</u>	Ibuprofen		Phenytoin	Rifabutin
Tolbutamide	Imipramine	<u>Azole</u>	(Dilantin)	Rifampin
Glipizide	(Tofranil)	Antifungals	Probenicid	Rifapentine
•	Indomethacin	Itraconazole	Retonavir	Secobarbital
Angiotensin II Blockers	Isoniazid	(Sporonox)	(Norvir)	
Losartan	Nateglinide	Ketoconazole	Sulfa-	
Irbesartan	Phenobarbital	(Nizoral)	methoxazole-	
	Phenytoin	Fluconazol	Trimethoprim	
<u>Sulfonylureas</u>	(Dilantin)	(Diflucan)	(Bactrim)	
Glyburide/glibenclamide	Piroxicam	Miconazole	Sulfaphenazole	
Glipizide	Retinoids	(Nystatin)	Sulfinpyrazone	
Glimepiride	Rosiglitazone	Voriconazole	Teniposide	
Tolbutamide	Rosuvastatin	(Vfend)	Ticlopidine	
	(Crestor)		Valproic acid	
<u>Miscellaneous</u>	Sildenafil	Miscellaneous	(Depakote)	
Alosetron (Lotronex)	(Viagra)	Amiodarone	Zafirlukast	
Amitriptyline	Sulfa Drugs	Cimetidine		
(Elavil)	Sulfaphenazole	(Tagamet)	Echinacea	
(demethylation)	Suprofen	Chloram-	Garlic (possible)	
Angiotensin	Tamoxifen	phenicol	Kava kava	
Carvedilol	THC	Clopidogrel	Milk thistle	
Celecoxib	(marijuana)	(Plavix)	(in-vitro/	
Chloramphenicol	Torsemide	Delavirdine	probably	
Clomipramine	(Demadex)	Disulfram	insignificant	
Coumadin	Valdecoxib	Efavirenz	in-vivo)	
(Warfarin)	S-warfarin	Etravirine	Saw palmetto	
Desogestrel	(active)	Fenofibrate	(in-vitro)	
Diazepam	Zolpidem	Fluorouracil	St. John's wort	
Diclofenac	(Ambien,	Fluvastatin	(in-vitro studies)	
Dronabinol	Edluar)	Gemfibrozil	(iii viao otaaico)	
Etravirine	(mostly CYP3A4)			

Continued...

CYP2C9 Continued...

CYP2C9: Down regulator - detoxifies coumarin and suflonylureas.

Note: Individuals with deficient CYP2C9 activity may be anti-coagulated on 0.5mg of coumadin/day, as they cannot efficiently clear S-coumadin. ARBs in these people may be ineffective because a pro-drug like losartan may be poorly activated.

Physician's Copy

CYP3A4

www.genovations.com\gdgen07

Health Implications: Cytochrome P450 3A4 is used in the metabolism of 50-60% of all prescription medications, most of our steroid hormones (cortisol, estrogen, testosterone, etc.) and organophosphate insecticides (e.g., parathion). The expression of CYP3A4 activity is easily induced and inhibited by various agents, with enzyme activity varying as much as 40-fold in humans. Although modestly reduced hepatic enzyme activity has been observed in carriers, the vast majority of studies suggest minimal impact of CYP3A4 polymorphisms on enzyme expression in vivo.

Minimizing Risks: Your health care provider has been provided a list of drugs cleared through CYP3A4. Drugs that are metabolized through this pathway will be cleared more slowly when other drugs or compounds that normally inhibit the enzyme (e.g., grapefruit juice) are also being taken. Consult your physician. Please refer to the drug pathway chart on the following page.

Milk thistle has been shown in vitro to inhibit CYP3A4 activity. Caution should be exercised in prescribing it, especially if the patient is taking pharmaceuticals cleared through CYP3A4.

Slow metabolizers have a significantly increased risk (up to 6-fold) of developing prostate cancer. Polymorphisms are associated with higher clinical stage and grade of these cancers, when present. Black men have the highest prevalence of both prostate cancer and of CYP3A4 polymorphisms.

Substrates	Inhibitors	Inducers
Glucocorticoids	<u>Antifungals</u>	Aminoglutethimide
Budesonide	Clotrimazole	Aprepitant
Ciclesonide	Fluconazol (Diflucan)	Barbiturates
Cortisol	Itraconazole (Sporonox)	Bexarotene
Dexamethasone (Decadron)	Ketoconazole (Nizoral)	Bosentan
Fluticasone (Advair, Flovent)	Miconazole	Calcitriol (vitamin D3)
Hydrocodone	Posaconazole	Carbamazepine
Hydrocortisone	Voriconazole	Dexamethasone
Methylprednisolone		Efavirenz
Mometasone	Antibiotics	Ethosuximide
Prednisolone	(NOT azithromycin)	Etravirine
Prednisone	Ciprofloxacin	Fosphenytoin
	Clarithromycin	Glucocorticoids
Sex Steroids	Erythromycin	Glutethimide
Androstenedione	Metronidazole	Griseofulvin
DHEA	Norfloxacin	Modafinil
Estraderm, Estrace	Telithromycin	Nafcillin
Estradiol	Troleandomycin	Nevirapine
Progesterone/progestins		Oxcarbazepine
Testosterone	HIV Anti-Virals	Phenobarbital
	Atazanavir	Phenytoin (Dilantin)
Oral Contraceptives	Darunavir	Pioglitazone
Ethinyl estradiol	Delaviridine	Primidone
Desogestrel	Etravirine	Troglitazone
Etonogestrel	Fosamprenavir	Rifabutin
Norethindrone	Indinavir	Rifampin
Levonorgestrel	Nelfinavir	Rifapentine
3	Ritonavir	Rufinamide (weak)
_Antifungals	Saquinavir	Troglitazone
Itraconazole (Sporonox)		lg
Ketoconazole (Nizoral)	_Miscellaneous_	St John's Wort (intestinal)
Miconazole (Monistat)	Acitretin	Garlic (possible)
Voriconazole (Vfend)	Amiodarone	Licorice (possible / animal study)
vendend2010 (viend)	Amprenavir	Libertoe (possible / ariintal stady)
<u>Antidepressants</u>	Aprepitant	
Amytriptyline (Elavil)	Azelastine	
Aripiprazole (Abilify)	Chloramphenicol	
Citalopram (Celexa)	Cimetidine	
Claiopram (Celexa) Clomipramine (Anafranil)	Conivaptan	
Ciompianine (Anananii)	Cyclosporine	

Patient: JANE DOE ID: Page 11

Physician's Copy

Continued...



CYP3A4

Continued...

Substrates		Inhibitors
Antidepressants cont.	Anti-Histamines	Miscellaneous cont.
Desvenlafaxine (Pristiq)	Astemizole (Hismanal)	Danazol
Imipramine (Tofranil)	Azelastine (Astepro)	Dasatinib
Nefazodone (Serzone)	Chlorpheniramine	Diltiazem
Mirtazapine (Remeron)	Fexofenadine (Allegra)	Diethyl-dithlocarbamate
Sertraline (Zoloft)	Loratadine (Claritin)	Efavirenz
Trazodone (Deseryl)	zorataanio (otantin)	Ethinyl estradiol
Ventlafaxine (Effexor)	HMG CoA Reductase Inhibitors	Fluoxetine (Prozac)
vertical axiii (Ellexel)	Amlodipine & atorvastatin (Caduet)	Fluvoxamine
<u>Benzodiazepines</u>	Atorvastatin (Lipitor)	Gestodene
Alprazolam (Xanax)	Cerivastatin (Epitor) Cerivastatin (Baycol/Lipobay)	Imatinib
Clonazepam (Klonipin)	Lovastatin (Mevacor) (NOT pravastatin)	Isoniazid
Diazepam (Valium)	(NOT rosuvastatin)	Lapatinib
Midazolam (Versed)	Simvastatin (Zocor)	Methylprednisolone
Temazepam (Restoril)	Simvastatin/Niacin (Simcor)	Mibefradil
Triazolam (Halcion)	Cirrivastatii/iviaciii (Cirricoi)	Midazolam
mazolam (naicion)	Ca++ Channel Blockers	Mifepristone
Sedatives/Tranquilizers	Amlodipine	Nefazodone
Aripiprazole (Abilify)	Bepiridil (Vascor)	Nicardipine
Buspirone (Buspar)	Carbamazepine (Tegritol)	Niconazole
Haloperidol (Haldol)	Cisapride (Propulsid)	Nifedipine
Zolpidem (Ambien, Edluar)	Diltiazem	Northindrone
Zoipidem (Ambien, Edidar)	Felodipine	Norfluoxetine
<u>Antibiotics</u>	Lercanidipine	Oxiconazole
Clarithromycin	Nicardipine	Prednisone
Clindamycin	Nifedipine	Quinine
Erythromycin	Nimodipine	Quinupristin
(NOT Azithromycin)	Nisoldipine	Roxithromycin
Telithromycin	Nitrendipine	Sertraline
renunomychi	Verapamil	Synercid
Proton-Pump Inhibitors	Veraparriii	Tamoxifin
Dexlansoprazole (Kapidex)		Troleandomycin
Esomeprazole (Nexium)		Verapamil
Lansoprazole (Prevacid)		Voriconazole
Omeprazole (Prilosec)		Zafirlukast
		Zileuton
Pantoprazole (Protonix)		
Rabeprazole (Aciphex)		

Page 12 Patient: JANE DOE ID: Physician's Copy

CYP3A4

Continued...

Substrates		Inhibitors
HIV Anti-Virals Amprenavir (Agenerase)	<u>Miscellaneous</u> Aflatoxin	Miscellaneous cont. Curcumin (in-vitro) Dang guai (in-vitro)
Delavirdine (Rescriptor)	Alfentanyl	Goldenseal/berberine (intestinal)
Efavirenz (Sustiva)	Almotriptan	Grapefruit (intestinal)
Indinavir (Crixivan)	Alosetron (Lotronex)	Milk Thistle (in-vitro/probably insignificant in-vivo)
Lopinavir (Kaletra)	Ambrisentan (Letairis)	Garlic (possible / in vitro)
Maraviroc	Amiodarone	Gallic acid
Nelfinavir (Viracept)	Aprepitant	(in wine and herbal teas-
Nevirapine (Viramune)	Benzopyrene	inhibition reduced by addition
Ritonavir (Norvir)	Bromocriptine	of ascorbic acid or GSH)
Saquinavir (Invirase)	Buprenorphine	Piper longum (pepper) (intestinal)
	Cannabinoids	Quercetin
Anti-Neoplastics	Cafergot	Saw palmetto (in-vitro)
Anastrozole (Arimidex)	Caffeine	Star fruit
Bexarotene	Certulizomab	Star Huit
Busulfan	Cevimeline	
Cyclophosphamide	Cilostazol	
Docetaxel	Cinacalcet	
Doxorubicin	Cisapride (Propulsid)	
Etoposide	Clopidogrel (Plavix)	
Exemestane (Aromasin)	Cocaine	
Fluvestrant	Codeine-N-demethylation	
Gleevec	Cyclobenzaprine	
Ifosfamide	Cyclosporine	
Imatinib	Dapsone	
Irinotecan	Dextromethorphan	
Ixabepilone	Dextromorphan	
Letrozole (Femara)	Dihydroergotamine	
Nilotinib	Disopyramide	
Paclitaxel	Dofetilide	
Taxol	Dolasetron	
Toremifene	Domperidone	
Vinblastine	Donepezil	
Vincristine	Dronabinol	
Vinorelbine	Dronedarone	
	Drospirenone & Estradiol	
	(Angeliq)	
	Dutasteride	
	Eplerenone	

CYP3A4 Continued...

Substrates

Miscellaneous cont. Miscellaneous cont.

Ergotamine Ranolazine Ethosuximide Repaglinide **Fentanyl** Rifabutin Finasteride (Propecia) Rifampin Flutamide Rimonabant Galantamine Rivaroxaban Glyburide (Micronase) Risperidone Isradipine Salmeterol LAAM Sibutramine Sildenafil (Viagra) Lapatanib

Levobupivacaine Sirolimus Lidocaine **Tacrolimus** Lasofoxifene Tamoxifen Losartan **Tiagabine** Methadone **Tolterodine**

Mifepristone Topiramate (Topamax)-only ~5%

Modafinil Tramadol Montelukast (Singulair) **Trimetrexate** Nateglinide Valdecoxib

Ondansetron Vardenafil (Levitra)

Oxybutynin R-warfarin Pimozide Zaleplon Pioglitazone Zileuton Propanolol Ziprasidone Quetiapine Zonisamide Quinidine Zotarolimus

Quinine

CYP3A4: Down regulator - detoxifies over 50% of all prescription medications and most steroid hormones.

Patient: JANE DOE ID: Page 14

Physician's Copy

Phase II Detoxification commentary is provided only for polymorphisms with known health implications.

+ - COMT V158M www.genovations.com/gdv158m

Clinical Implications: Catechol-O-methyltransferase (COMT) inactivates catecholamines, catechol estrogens, and catechol drugs such as L-DOPA. A polymorphism in COMT results in reduced COMT activity, thus decreased degradation of these compounds. Risk may be increased for some neuropsychiatric disorders, impaired estrogen metabolism, and increased sensitivity to pain.

Individuals carrying the M allele (+) have moderately reduced clearance of catecholamines from neural synapses. The polymorphism is associated with improved cognition due to higher amounts of synaptic dopamine. Risk is increased, however, for anxiety, mood disorders, and ultra rapid cycling in bipolar disorder. Risk is also increased for breast cancer (if prolonged estrogen exposure), hypertension (at least in men), and fibromyalgia.

Minimizing Risks: Minimize sustained mental and environmental stress, as adrenaline levels may already be high. Stress hormones also require COMT for their degradation, thus can decrease the methylation of estrogen compounds. Ensure adequate intake of B vitamins, magnesium, and protein.

Avoid high homocysteine (S-adenosylhomocysteine inhibits COMT). Ensure adequate antioxidants to prevent oxidation of pro-carcinogenic 4-hydroxyestrogens. Use caution with amphetamine-based medications and catechol drugs. Use caution with conjugated equine estrogens (e.g., Premarin®), as 4-hydroxyequilenin is more likely to inhibit COMT in carriers of the polymorphism. Also be careful with amphetamine-based medications. Breast cancer risk is increased with long-term estrogen replacement and in women who also have a GST polymorphism. Vitamin B6 appears to be helpful to Parkinson's patients.

Physician Recommendations:

+ - NAT2	I114T	www.genovations.com/gdi114t
+ - NAT2	R197Q	www.genovations.com/gdr197q

Health Implications: N-acetyltransferase 1 is found in extra-hepatic tissues, while NAT2 is found predominantly in the liver and the gut. Both are used in the Phase II acetylation of numerous environmental toxins, including heterocyclic aromatic amines. Slow acetylators do not clear toxins well and the resulting increased total toxic burden can increase the risk of lung, colon, breast, bladder, and head and neck cancers, though results have not been consistent in all studies. Urinary bladder cancer appears to have the most consistent association with slow acetylation.

Minimizing Risk: If you smoke, stop. Your risk of lung cancer is substantially higher than someone with normal NAT activity. Even occasional smoking or exposure to second hand smoke is harmful. Liberal consumption of most vegetables and fruits but especially cruciferous vegetables (broccoli, Brussels sprouts, cauliflower, watercress, and cabbage), garlic, onions, soy, grapes and berries will increase Phase II efficiency, including acetylation.

+- NAT2 K268R www.genovations.com/gdk268r

Health Implications: N-acetyltransferase 1 is found in extra-hepatic tissues, while N-acetyltransferase 2 is found predominantly in the liver and the gut. NAT2 is the enzyme that controls Phase II acetylation of numerous environmental toxins, including heterocyclic aromatic amines. Rapid acetylators increase O-acetylation of toxins that can actually make the toxins more reactive. These transformed toxins may increase risk of developing lung, colon, breast, bladder, head and neck cancer, though results have not been consistent in all studies. Colon cancer appears to have the most consistently reproducible association with fast acetylation.

Minimizing Risk: If you smoke, stop. Your risk of lung and breast cancer is substantially higher than someone with normal NAT activity. Do not eat fried foods and minimize red meat as these substantially increase your risk of colorectal cancer. Avoid well-done meats as these may substantially increase your risk of breast cancer. Liberal consumption of most vegetables and fruits but especially cruciferous vegetables (broccoli, Brussels sprouts, cauliflower, watercress, and cabbage), garlic, onions, soy, grapes and berries will increase Phase II efficiency, including acetylation.

Physician Recommendations:

ABSENT	GSTM1	1p13.3	www.genovations.com/gdgstm1
+-	GSTP1	A114V	www.genovations.com/gda114v
++	GSTP1	I105V	www.genovations.com/gdgstp1

Health Implications: Glutathione S-transferases (GST) are responsible for detoxifying certain products of oxidative stress and a variety of electrophilic xenobiotics and carcinogens such as solvents, herbicides, pesticides, polycyclic aromatic hydrocarbons, steroids, and heavy metals. GSTM1 is located primarily in the liver, whereas GSTP1 is located primarily in the brain and lungs.

When there is no gene present on the GSTM1 chromosome it is called an "absent" allele. This results in reduced capacity for hepatic detoxification and increased risk of various cancers, chemical sensitivity, coronary artery disease in smokers, atopic asthma, and deficits in lung function. Risk appears *reduced* for colorectal- and head & neck cancer, but *only* when cruciferous vegetable intake is high.

GSTP1 polymorphisms are associated with either higher or lower enzyme activity, depending on the exposure. These GSTP1 genotypes are associated with increased risk of various cancers, risk that is compounded by exposure to cigarette smoke and the "absent" GSTM1. Risk may also be increased for late-onset Alzheimer's, and Parkinson's disease in smokers.

Minimizing Risk: Minimize exposure to cigarette smoke, charred food, herbicides, fungicides, insect sprays, industrial solvents, and toxic metals. Ensure availability of glutathione (GSH) precursors and cofactors, e.g., methionine, N-acetylcysteine, glutamine, glycine, magnesium, and pyridoxal-5-phosphate (B6). GSH depletion may be reduced by alpha lipoic acid, milk thistle, and taurine. Allium vegetables (e.g., onions, leeks, garlic) and crucifers (e.g., broccoli, cauliflower, cabbage, kale, Brussels sprouts, radish sprouts) can increase GST activity and reduce cancer risk. Consume an antioxidant-rich diet to prevent oxidative stress.

Physician's Copy

+ + SOD2

A16V

www.genovations.com/gda16v

Health Implications: Superoxide dismutase is the primary anti-oxidant enzyme within the mitochondria of cells (where most of our energy is made). SOD2 converts reactive oxygen species into less reactive hydrogen peroxide. Polymorphisms in SOD2 (+/- and +/+) are associated with reduced SOD activity. While this may increase some risk of oxidative stress, more clinical correlations have been observed for the (-/-) genotype. This genotype has specifically been associated with increased risk of cardiomyopathy.

Minimizing Risk: Although this genotype is less sensitive to antioxidant status compared to the (-/-) genotype, liberal consumption of dietary antioxidants in colorful vegetables and fruits is still recommended. Broad-spectrum antioxidant supplements may also be helpful, as well as manganese, which serves as a cofactor for SOD2. Consult your health care provider to find the supplement regimen that best fits your overall health anti-oxidant needs.